Knaus Tabbert AG

  • WKN: A2YN50
  • ISIN: DE000A2YN504
  • Land: Deutschland

Nachricht vom 30.09.2021 | 07:44

Knaus Tabbert AG withdraws guidance for the 2021 financial year due to increasing shortage of materials

Knaus Tabbert AG / Key word(s): Forecast/Annual Results
Knaus Tabbert AG withdraws guidance for the 2021 financial year due to increasing shortage of materials

30-Sep-2021 / 07:44 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Due to increasing shortages of materials along the supply chain, the Executive Board of Knaus Tabbert AG is withdrawing its guidance for sales and profit margin for the 2021 financial year. The medium-term growth expectation is not affected by this. The previous guidance had last been confirmed on August 11, 2021, and was already subject to further restrictions in connection with problems in the supply chain. In that guidance, the company assumed sales growth in the lower range of 20 to 22 percent and an adjusted EBITDA margin of around 8 percent.

Ongoing delays in the supply of chassis, primarily related to the global semiconductor shortage, mean that the production lines for motor homes at the sites in Jandelsbrunn (Germany) and Nagyoroszi (Hungary) will have to be stopped in the fourth quarter - for an expected period of at least two weeks - and, in addition, working hours at these sites will be significantly reduced.

In view of the dynamics of the developments in connection with supply shortages, a new forecast with regard to revenue and adjusted EBITDA for the 2021 financial year and thus on the business development of Knaus Tabbert can only be made at a later date.

Contact Media Relations                                            Contact Investor Relations
Stefan V. Diehl                                                            Manuel Taverne
mobil: +49 (0) 162 9081044                                          mobil: +49 (0) 152 02092909
e-Mail:                                   e-mail: 

30-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021